Trial Profile
Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary) ; Levosimendan (Primary)
- Indications Pulmonary hypertension
- Focus Proof of concept; Therapeutic Use
- Sponsors Tenax Therapeutics
- 10 Oct 2022 Results presented in a Tenax Therapeutics media release.
- 10 Oct 2022 According to a Tenax Therapeutics media release, data from the trial were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022.
- 04 Jan 2022 According to a Tenax Therapeutics media release, Data from the transition substudy confirms that oral levosimendan, when dosed at 3-4 mg per day, was safe, well-tolerated, and maintained the efficacy of IV levosimendan.